ReviewReviews in medical virology2026
Regional and Temporal Dynamics of Dengue in Mexico (2020-2024): A Comprehensive Epidemiological Analysis.
Review in Reviews in medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Dengue remains a major public health concern in Mexico, with incidence and clinical burden increasing substantially in recent years. Using national surveillance data from 2020 to 2024, this study provides a comprehensive overview of the changing epidemiological landscape, with an emphasis on geographic distribution, temporal trends, serotype dynamics, and disease severity. Over this period, Mexico saw an almost fivefold increase in dengue cases, reaching over 123,000 confirmed infections and 426 deaths in 2024, the highest annual number recorded. Seasonal patterns shifted, with sustained transmission extending into unusual winter months from late 2023. Serotyping data revealed a shift in predominant virus serotypes, with DENV2 predominating until 2022, DENV1 peaking in 2021, and DENV3 rising sharply from 2022 onward, becoming dominant in 2023 and almost exclusive by 2024. This shift coincided with a sustained rise in dengue with warning signs (from 16.9% in 2020 to > 42% in 2023-2024) and higher hospitalisation rates, while severe dengue remained below 5%. Although DENV3 dominated nationally, DENV1 and DENV2 persisted in specific states, and DENV4 circulated sporadically, particularly in southern and northern regions. Several traditionally low-prevalence states experienced atypical outbreaks, underscoring the potential for sudden epidemic expansion. Climatic analysis showed a consistent positive association between temperature and DENV3 prevalence, with precipitation effects varying by year. Odds ratio analysis suggested serotype-specific differences in severity across years. These findings underscore the heterogeneous and dynamic nature of dengue transmission in Mexico and highlight the need for regional surveillance, prevention, and clinical preparedness strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.